Get the Stockscreener App
1.32
3.13%
0.04
After Hours:
1.32
Humacyte Inc stock is traded at $1.32, with a volume of 3.06M.
It is up +3.13% in the last 24 hours and down -22.81% over the past month.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.
See More
Previous Close:
$1.28
Open:
$1.27
24h Volume:
3.06M
Relative Volume:
0.60
Market Cap:
$247.20M
Revenue:
-
Net Income/Loss:
$-110.78M
P/E Ratio:
-1.2336
EPS:
-1.07
Net Cash Flow:
$-75.59M
1W Performance:
+10.00%
1M Performance:
-22.81%
6M Performance:
-47.83%
1Y Performance:
-69.16%
1-Day Range:
$1.24
$1.32
1-Week Range:
$1.09
$1.32
52-Week Range:
$1.09
$6.77
Humacyte Inc Stock (HUMA) Company Profile
Name
Humacyte Inc
Sector
Industry
Phone
919-313-9633
Address
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
Compare HUMA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
1.32 | 239.71M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-27-25 | Initiated | Barclays | Overweight |
| May-14-25 | Resumed | H.C. Wainwright | Buy |
| Dec-20-24 | Reiterated | H.C. Wainwright | Buy |
| Dec-11-23 | Initiated | H.C. Wainwright | Buy |
| Aug-14-23 | Upgrade | Piper Sandler | Underweight → Neutral |
| Jun-22-23 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-22 | Downgrade | Piper Sandler | Overweight → Underweight |
| Oct-29-21 | Initiated | Cowen | Outperform |
| Sep-24-21 | Initiated | Oppenheimer | Outperform |
| Sep-22-21 | Initiated | BTIG Research | Buy |
| Sep-16-21 | Initiated | Piper Sandler | Overweight |
View All
Humacyte Inc Stock (HUMA) Latest News
Humacyte’s Major Breakthroughs Impress Investors: Market Reactions - StocksToTrade
Humacyte Inc. (HUMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
D. Boral Capital Maintains Humacyte (HUMA) Buy Recommendation - MSN
Humacyte (HUMAW) Stock Price, News & Analysis - MarketBeat
Humacyte, Inc. (HUMA) stock price, news, quote and history - Yahoo Finance UK
Quantitative breakdown of Humacyte Inc. recent moveMarket Movers & Long-Term Growth Plans - newser.com
Humacyte releases press info on VEITH symposium presentation - Traders Union
D. Boral Capital Reiterates "Buy" Rating for Humacyte (HUMA) | H - GuruFocus
Humacyte Announces Presentations at VEITHsymposium Highlighting Positive Acellular Tissue Engineered Vessel (ATEV™) Clinical Results - The Manila Times
Humacyte (Nasdaq: HUMA) Details ATEV Recellularization and 2-Year Trauma Data - Stock Titan
What recovery options are there for Humacyte Inc. Equity WarrantWeekly Profit Summary & Long-Term Capital Growth Strategies - newser.com
Real time pattern detection on Humacyte Inc. stockPortfolio Gains Report & Step-by-Step Trade Execution Guides - newser.com
Will Humacyte Inc. Equity Warrant stock see insider buyingDividend Hike & Real-Time Stock Movement Alerts - newser.com
Will Humacyte Inc. see short term momentumJuly 2025 Sector Moves & Stepwise Trade Execution Plans - newser.com
Will Humacyte Inc. stock deliver shareholder valueJuly 2025 Summary & Risk Controlled Daily Plans - newser.com
Is Humacyte Inc. stock supported by strong cash flows2025 AllTime Highs & Low Risk Growth Stock Ideas - newser.com
How to interpret RSI for Humacyte Inc. stock2025 Valuation Update & Precise Buy Zone Identification - newser.com
Multi asset correlation models including Humacyte Inc. Equity WarrantWeekly Trade Review & Verified Short-Term Plans - newser.com
Is Humacyte Inc. Equity Warrant stock ready for a breakoutInsider Selling & Real-Time Price Movement Reports - newser.com
Is Humacyte Inc. Equity Warrant stock attractive for retirement portfolios - newser.com
Is Humacyte Inc. Equity Warrant stock attractive for growth ETFsQuarterly Trade Review & Daily Risk Controlled Trade Plans - newser.com
Will Humacyte Inc. stock benefit from infrastructure spendingEarnings Risk Summary & High Accuracy Trade Signal Alerts - newser.com
Using RSI to spot recovery in Humacyte Inc. Equity Warrant2025 Earnings Surprises & Safe Swing Trade Setup Alerts - newser.com
Humacyte Inc: Is It a Time of Strategic Shift? - StocksToTrade
[Form 4] Humacyte, Inc. Insider Trading Activity - Stock Titan
Humacyte introduces Symvess at Veith Symposium - Traders Union
Technical analysis overview for Humacyte Inc. Equity Warrant stockJuly 2025 Opening Moves & Detailed Earnings Play Strategies - newser.com
Earnings visualization tools for Humacyte Inc.Market Rally & Weekly Stock Performance Updates - newser.com
Chart overlay techniques for tracking Humacyte Inc.2025 Biggest Moves & Daily Risk Controlled Trade Plans - newser.com
Can Humacyte Inc. stock reach $100 price targetJuly 2025 PostEarnings & AI Based Buy/Sell Signal Reports - newser.com
Key metrics from Humacyte Inc.’s quarterly dataQuarterly Portfolio Summary & AI Powered Market Entry Ideas - newser.com
Should I hold or sell Humacyte Inc. Equity Warrant stock in 2025Chart Signals & Verified Short-Term Plans - newser.com
Will Humacyte Inc. stock attract more institutional investorsLong Setup & Weekly Return Optimization Plans - newser.com
Is Humacyte Inc. stock trading near support levels2025 Price Targets & Reliable Breakout Stock Forecasts - newser.com
What analysts say about Humacyte Inc Equity Warrant stockMarket Breadth Indicators & Outstanding Capital Returns - earlytimes.in
Is Humacyte Inc. stock cheap compared to fundamentalsJuly 2025 Pullbacks & Expert Verified Movement Alerts - newser.com
Humacyte Inc Stock (HUMA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.53%
1.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):